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Explanation Regarding the Proposed Grant: Patients and 
health care providers were discussing the possibility of do-
ing a multiple drug “cocktail” trial for amyotrophic lateral 
sclerosis (ALS). When this U01 PRA/RFA grant oppor-
tunity was released in 2015 we thought it might be a good 
vehicle to attempt to get this funded. The goal was to lever-
age multiple sites funded by NIH Clinical and Translational 
Science Awards (CTSA sites) and also include other sites 
(total 25 sites). After a great deal of discussion, we decided 
on a three-arm study and the drug cocktail was designed to 
potentially attack the pathophysiologic processes of neuro-
inflammation, motor neuron hyperexcitability and gluta-
mate excitotoxicity. In all three study arms patients were to 
receive standard of care which included access to riluzole, 
PEG, BIPAP and then they would be randomly assigned to 
one of three arms:
1) tamoxifen (20mg: 2 times/day) and ranolazine 
(500 mg: 2 times a day
2) tamoxifen (20mg: 2 times/day) and mexiletine 
(200 mg: three times/day
3) tamoxifen (20 mg: 2 times a day) and memantine 
(20 mg: 2 times/day)
Subjects were to be randomly assigned using a Bayesian 
adaptive design process that we used successfully in the 
PCORI funded comparative effectiveness drug study for 
neuropathic pain.
We called the project ALS PATIENTs DEMAND 
which stood for the ALS Patient-Driven Electronic-based 
Multidrug Adaptive Network Design clinical trial
Because the grant was to NCATS and the goal was to 
introduce novel trial designs that could be extrapolated to 
other diseases, we also had an aim to utilize a number of 
new initiatives to streamline regulatory oversight, ensure 
meaningful patient -engagement, enhance recruitment and 
decrease the burden of outcome collection.
We divided the sites into three regions and proposed to 
use IRB reliance models at U California -Irvine on the west 
coast (Dr. Tahseen Mozaffar as Irvine sites PI and leader 
of the west coast group), at Univ. Kansas as the lead in the 
Greater Plains Collaborative PCORnet network, (Dr. Jef-
frey Statland as site PI) and in the NIH Create consortium 
based in Miami (Dr. Michael Benatar site PI and leader of 
the CReATe group).
We proposed to use the then recently created EPIC 
downloadable ALS clinic templates to collect the data.
We proposed two-way video web-based interactions 
with patients so they would not have to come in for as many 
visits.
We believed the study could create a model for multi-
center research studies seeking to more efficiently maxi-
mize network-level collaborations to study any rare disease.
This was an ambitious proposal that did get scored (41) 
but this was not in a fundable range.
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At the time these U01 grants allowed for direct costs of 
nearly 1 million dollars a year for 5 years.
We had to apply via an XO2 preproposal mechanism 
to apply for the large study. The XO2 was submitted in the 
summer of 2015 and was accepted in the fall of 2015. We 
submitted the full proposal in early 2016.
We have attached PDFs of the Specific Aims page, the 
Research plan, and the Critiques.
The reviewers were very critical of our attempt to use 
three IRBs to control the study and in retrospect this was 
a valid criticism. They stated this could potentially jeop-
ardize the safety of the study. This is why they concluded 
the protection of human subjects “was unacceptable” along 
with some toxicology concerns. Even with the three central 
IRB approaches we still had intended for Univ Kansas to 
be the primary CCC/DCC, but this did not come across in 
the proposal. They thought we were saying the three CTSA 
hubs (Kansas, Miami, Irvine) each were responsible for all 
the DCC/CCC activities of the sites using their IRBs. That 
was not our intention.
Regarding the cocktail approach, some of the reviewers 
thought this was not novel as it had been used in cancer and 
HIV studies. We felt these reviewers did not appreciate the 
difficulties in doing this for ALS.
Only one reviewer addressed the drugs in the cocktail. 
They stated tamoxifen was not well justified and that each 
drug had side effect profiles and that the side effects of each 
drug “could be viewed as exacerbating the ALS disease pro-
cess”!
They really liked the Bayesian adaptive design.
In talking to leaders at NCATS after we received the 
critiques, they encouraged us not to do a cocktail study.
When we resubmitted the proposal, we engaged the 
new NIH funded Trial Innovation Network resources. Johns 
Hopkins is one of the TINS and we applied for a consulta-
tion on how to improve our proposal and we were accepted 
into the TIN program. We worked for nearly a year to im-
prove the application and resubmitted with more simplified 
trial design comparing mexiletine and ranolazine and also 
randomizing sites to enrolling subjects as traditional urban 
research centers (TURCs) or mobile innovation research 
centers (MIRCs) to also test the hypothesis that we can just 
as easily do research remotely. This application did not do 
much better with a score of 40. We continued to work with 
the TIN and now we believe we have further improved the 
trial which was resubmitted in March 2020.
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1. Specific Aims 
New translational science tools and approaches for more rapidly advancing health research to the common 
goal of improved cures and treatments are especially needed for studies of rare diseases.  The goals of this 
application are 1) to create a model for leveraging existing national research initiatives and new translational 
science tools to build the infrastructure to run multi-site studies in rare diseases; and 2) for proof of concept, to 
use this CTSA-based national research infrastructure to test the hypothesis that drug combination therapy in 
amyotrophic lateral sclerosis (ALS) will be more effective than standard of care alone. ALS is a rare 
progressive neurodegenerative disease which is uniformly fatal.  Traditional approaches to developing 
therapies have failed in ALS, yielding only a single FDA approved therapy with a modest benefit on survival.  
Thus, there is a pressing need for new therapeutic approaches in ALS. One such approach used to treat 
cancer and HIV has been drug combinations targeting different pathological pathways.  We convened an ALS 
patient and caregiver focus group who expressed overwhelming interest in using a drug ‘cocktail’ approach to 
ALS therapy. Patients also frequently state they feel left out or abandoned once their disease progresses 
beyond the earliest stages, the most common focus of most ALS clinical trials. Therefore, we designed a 
patient-driven clinical trial to assess which of three drug cocktails targeting different pathological pathways are 
the most effective in slowing disease progression in ALS: the ALS Patient-Driven Electronic-based Multidrug 
Adaptive Network Design clinical trial (ALS PATIENTs DEMAND). For ALS PATIENTs DEMAND we will 
leverage existing major initiatives to simplify the regulatory process, to connect electronic health records 
(EHRs) of large academic ALS centers, and to roll out common data elements through the EHR and via CTSA 
funded REDCap databases to build a large national ALS clinical trial network—providing the bandwidth to 
study large numbers of ALS patients, and importantly, to broaden study inclusion criteria to include ALS 
patients often excluded from traditional clinical trials. 
 
Aim 1: To leverage existing research initiatives and introduce new innovations to streamline regulatory 
oversight, ensure meaningful patient-engagement, enhance recruitment, decrease the burden of 
outcome collection, and hasten results dissemination using 3 CTSA Coordinating Centers and 25 sites 
(19 CTSAs).  Specifically: 
a. We will compare the regulatory efficiencies across 3 different networks: two IRB reliance models 
(Greater Plains Collaborative: a PCORNet CDRN; and the University of California Regulatory System); and 
one central IRB (the ALS Rare Disease Clinical Research Network).  We will compare the time to regulatory 
approval, time from regulatory approval to first patient enrollment, and rates of accrual. 
b. We will create a patient engagement plan which incorporates the patient voice into all aspects of the 
clinical trial: protocol development, recruitment, retention, study conduct, and dissemination of results.  
c. We will use EHR-defined computable phenotypes for patient screening, and compare this approach to 
traditional recruitment strategies in the clinic or via patient advocacy groups. 
d. We will leverage the availability of EPIC downloadable ALS clinic templates for the primary set of 
outcomes to compare outcomes collected by this EHR-i2b2 interface with those collected by using REDCap 
database links within the local clinic work-flow. We also will explore whether this approach reduces the burden 
on patients, caregivers, and health care providers. 
e. We will implement a patient visit and adverse event monitoring system via a two way web-based video 
system already in production to reduce the burden of participation and ensure retention. 
 
Aim 2: To determine which of three drug regimens added to standard of care has the greatest efficacy 
for slowing ALS disease progression.  For this aim we will conduct a prospective 12 month three-arm 
Bayesian response adaptive randomization clinical trial. Drug combinations will repurpose FDA approved 
drugs for other indications which act on potential ALS pathological pathways (neuroinflammation, motor neuron 
hyperexcitability, and glutamate excitotoxicity). Informative priors and stopping criteria will be derived from the 
PROACT data base of 8500 patients.  The diverse ALS population in our national ALS network (over 4700 
patients) and the informative priors derived from PROACT will allow us to broaden our inclusion criteria to 
include patients often excluded from current clinical trials. 
 
Our proposed collaboration among CTSA coordinating centers to create a model for assembling study-specific 
infrastructure for rare diseases will not only serve as a blueprint for future clinical trials in ALS, but also will 
inform any multi-center clinical trials seeking to more efficiently maximize network-level collaboration to study 
any disease. 
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2. Research Strategy 
A. Statement of the Problem and its Significance to Translational Science 
The goal of this application is to create a model whereby we will leverage existing national research initiatives 
and translational science tools to create the infrastructure needed to run multi-site studies in rare diseases.  
We intend to show that deploying innovative translational science approaches can accelerate testing of 
putative therapeutics for rare diseases.  By definition a rare disease in the US is one where < 200,000 people 
are affected; however, taken together there are approximately 7000 rare diseases(1).  This represents a 
significant burden to the US health care system. Barriers to developing new therapies for rare diseases 
include: 1) the need to use multiple sites to recruit sufficient numbers of patients to obtain statistical rigor; 2) 
difficulties with regulatory oversight for large multicenter studies causing delays in start-up and increasing 
study costs; 3) difficulties with assembling efficient networks for data collection, while minimizing patient 
burden; 4) ensuring patient and caregiver voices are heard throughout the therapeutic development process; 
5) using technology to overcome barriers in distance or medical infirmity to allow all eligible patients to 
participate in the research enterprise.  The national CTSA system gives us an unprecedented opportunity to 
use our existing infrastructure to build on the models for IRB reliance, use the national REDCap database 
infrastructure, use CTSA based patient engagement initiatives, leverage new health care technology 
development, and formalize existing multi-institution relationships to address a large unmet medical need.  We 
propose to leverage the broad CTSA-based national research infrastructure and the regulatory structure of 3 
established clinical research networks to conduct a clinical trial in amyotrophic lateral sclerosis (ALS). 
 
ALS is a progressive uniformly fatal neurodegenerative disease.  The median age of onset is between 50 and 
60 years, where individuals are at the peak of earning, which places a tremendous financial and emotional 
burden on patients, family members, and their communities(2).  ALS is characterized by spasticity and 
hyperreflexia from the loss of upper motor neurons in corticospinal tracts and from muscle weakness, 
fasciculations, and atrophy due to lower motor neuron degeneration and death in the anterior horns of the 
spinal cord(3). Disease progression leads to limb paralysis, loss of speech, swallowing, and respiratory 
functions, and ultimately death. While ALS is regarded as a rare disease, affecting only ~21,000 people in the 
US at any point in time, the incidence (at 2 per 100,000) matches that of common neurological diseases such 
as multiple sclerosis(4-6).  Moreover the lifetime risk of dying from ALS is about 1 in 400(7).  ALS therefor 
appears rare only because we have no effective therapies and because the disease is fatal. 
 
Traditional approaches to therapy development have so far failed in ALS, yielding only one FDA approved 
drug, Riluzole, which prolongs life by 2-3 months(8, 9).  The current standard of care for ALS patients is 
primarily supportive with the goal of maximizing quality of life(10). The 2009 American Academy of Neurology 
recommendations for the management of ALS patients state that in addition to Riluzole, enteral nutrition via 
percutaneous endoscopic gastrostomy (PEG) should be considered to stabilize body weight in patients with 
impaired oral intake, and noninvasive ventilation (NIV) should be offered in order to prolong survival and slow 
the impact of declining forced vital capacity (FVC). PEG or NIV can extend life by approximately 6 months if 
the treatments are adhered to and applied early(10, 11). 
 
Since traditional approaches to therapy development have failed, we urgently need to apply innovative 
translational science approaches to ignite a paradigm shift in the way we approach therapy development for 
this fatal neurodegenerative disease(12). Thus, as a first test of our proposed approach, we will establish the 
ALS Patient-Driven Electronic-based Multidrug Adaptive Network Design (ALS PATIENTs DEMAND) 
infrastructure needed specifically for studying ALS treatment options and determining which of three drug 
combination regimens has the greatest effect on slowing ALS disease progression.  
 
The significance of this project is: 1) it will present a model for leveraging existing national infrastructure and 
translational science innovations for clinical trials in rare diseases; and 2) it will answer the question of whether 
drug combinations work better than standard of care in ALS, which would have an impact on patient care. 
 
B. Rationale 
Establishing an innovative CTSA-based national research infrastructure will allow us to contribute to advancing 
translational science by critically assessing innovations such as patient-engagement, streamlining regulatory 
oversight, and using other new initiatives (e.g., IRB reliance agreements) and translational science tools (e.g.,  
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EHR-i2b2 interface capabilities for downloadable clinic templates).  Our project also is innovative in being the 
first to rigorously test the efficacy of drug combination regimens for ALS. 
 
Accumulating evidence points to multiple pathological processes being active in ALS – this raises concerns 
that the disease cannot be halted or slowed by simply targeting one of these mechanisms.  Important lessons 
for approaching ALS can be learned from other diseases: in HIV they found that only by targeting multiple 
steps in the pathological cascade could they affect a significant health impact on controlling HIV; and in cancer 
the use of combination therapies which target multiple pathological pathways has essentially become standard 
of care for many malignancies (3, 13, 14).  The exact underlying cause of ALS motor neuron degeneration may 
remain uncertain; however, convincing evidence, supports the role of a number of pathological pathways—
including glutamate excitotoxicity, neuroinflammation, and motor nerve hyperexcitability (15-17).  Each of these 
pathways has FDA approved drugs for other indications than ALS currently available on the market.  Many of 
these drugs have shown promise in ALS studies in vitro, in animal models, or in small often underpowered 
clinical trials(18).  This is frustrating to both patients and clinical researchers, as many currently available and 
potentially effective drugs are not being tried or are being discarded in ALS due to lack of money or initiative.  
We have convened two patient and caregiver focus groups who have expressed overwhelming interest in 
using a drug ‘cocktail’ approach to ALS therapy. By creating drug combination regimens which target multiple 
pathological pathways we may be able to slow progression in a more profound and lasting fashion than any 
one drug alone. 
 
The ability to obtain statistical rigor to test drug combination regimens in ALS requires large number of patients 
and multiple sites participating across the country.  ALS patients are seen in either an Amyotrophic Lateral 
Sclerosis Association (ALSA) or Muscular Dystrophy Association (MDA) sponsored clinics, usually at tertiary 
care centers. While the vast majority of our ALS patients are seen in ALS specialty clinics, most of which are 
affiliated with CTSA academic centers, our ability to pool resources and recruit large populations of ALS 
patients for studies has been limited.  This is not due to lack of interest from patients.  The existing CTSA 
national infrastructure, combined with three large existing network initiatives, provide an unprecedented 
opportunity to consolidate resources and build on these existing initiatives to advance translational science. 
 
With respect to the specific proposed trial, if any of the tested drug combinations prove effective in ALS; this 
will have a dramatic and immediate impact on patients, their family members, and communities.  All of the 
proposed drug combinations repurpose FDA approved medications currently used for other indications which 
should all be available in generic preparations by completion of this trial.  Thus, most ALS patients could obtain 
immediate access to and benefit from these proposed treatments.  
 
Equally important, if the study design innovations proposed here prove feasible this may not only transform the 
way we approach clinical trials in ALS and rare diseases, but also will inform any multi-center clinical trials 
seeking to more efficiently maximize network-level collaboration to develop new therapeutics for any disease. 
 
C. Strategy and Methodology 
Aim 1a. We will compare the regulatory efficiencies across 3 different networks: two IRB reliance models and 
one central IRB. 
Collaboration: In order to maximize efficiency and streamline design of the ALS PATIENTs DEMAND 
infrastructure we will leverage three existing research networks (Figure 1): 
 We will designate three CTSA Coordinating Centers (CTSA CC), each of which plays a key role in an 
established research network. 
 The CTSA CCs will share the workload of reviewing the 25 sites, thus gaining efficiencies in the start-
up process. 
 There are 5 sites not affiliated with a CTSA CC. These unaffiliated sites will be added to a CTSA CC. 
 All sites are ALS specialty centers with long histories of working together in smaller existing research 
consortia: i.e. the Western ALS Study Group, the Northeast ALS Consortium, the ALS Research Group, 
or in prior investigator-initiated ALS studies.  
The three research networks included in this study are: 1) the Patient Centered Outcomes Research 
Network (PCORnet) Greater Plains Consortium (GPC) (19),  2) The University of California Biomedical 
Research Acceleration, Integration, and Development (UC BRAID)(20), and  3) The Clinical Research in  
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ALS and Related Disorders for Therapeutic Development (CReATe), a Rare Diseases Clinical Research 
Consortium that forms part of the NIH’s Rare Diseases Clinical research Network.  Within the GPC there 
are ALS specialty clinics that already have demonstrated the ability to combine resources to perform ALS 
research by conducting a survey of ALS patients using a single IRB of record.  UC BRAID also has mature 
reliance architecture in place which will be used for this study. CReATe has an ongoing natural history study to 
better understand the phenotypic variability in ALS (that will not compete with the current proposed study), and 
a central IRB model in place.  Part of CReATe is the ALS patient registry (CReATe Connect), with hundreds of 
ALS patients registered, who have agreed to be contacted for future studies. 
Our organizational structure will include one CTSA CC site representing each of the above networks, and 25 
ALS specialty centers spread across the country (20 CTSAs, Figure 1). These CTSA CCs will be: 1) the 
University of Kansas Medical Center (KUMC) which serves as the data coordinating site for the GPC and the 
overall lead site for this study; 2) The University of California Davis (UC-Davis), which will coordinate with the 
UC BRAID system; and 3) The University of Miami, which serves as the main coordinating site for CReATe.  
 
Figure 1. The three CTSA 
CCs and their existing 
research networks include 
25 academic centers. The 
numbers represent 
estimated ALS clinic 
populations.  Yellow=UC 
BRAID, Blue=GPC, Green 
= CReATe, MDA = 
Muscular Dystrophy 
Association Clinic, ALSA = 
Amyotrophic Lateral 
Sclerosis Association 
Clinic, WALS = the 
Western ALS Study 
Group, NEALS = the 
Northeast ALS 
Consortium. Dotted lines 
represent sites not currently in GPC, UC BRAID, or CReATe. 
 
The organization structure will stem from the 3 CTSA CCs.  We will compare the existing IRB regulatory 
models of these networks on key study timelines. 
 
The GPC, UC BRAID and CReATe will be responsible for providing regulatory oversight of institutions in their 
existing networks.  The workflow will include: Each of the CTSA CC ALS physicians will interact the with an 
ALS PATIENTs DEMAND steering committee (see below) to produce the final study protocol; and then the 3 
CTSA CC regulatory members will create a common informed consent form. The KUMC IRB will coordinate 
with the other two CTSA CCs to facilitate communication and administration of regulatory tasks necessary for a 
successful start-up.  The KUMC IRB is well situated to lead this cooperative model, and:  
 Has experience in serving as the coordinating center for 3 PCORI funded trials, 
 Has a dedicated reliance coordinator, 
 Will lead development of the universal consent form to be used at all sites and customized only in 
limited areas relevant to local information (this important step will speed the approval of consent and 
other patient-facing materials by the 3 IRBs), 
 Will centralize version control for all materials submitted to the three reviewing IRBs, and  
 Will disseminate any updates to protocol or patient materials, safety monitoring updates (adverse 
events, DSMB reports, etc.) 
 
A study steering committee was established for the design phase of this study and included: each of the CTSA 
CC PIs and ALS doctors, a patient representative, the study informatics officer, statistician, a PhD pharmacist, 
and representatives from patient advocacy groups.  In addition the steering committee sought specific input  
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from patients who had participated in prior focus groups who agreed to be contacted for this study. 
 
Innovation: Our innovation is creating a nation-wide ALS PATIENTs DEMAND infrastructure not only to 
perform a large multi-center ALS clinical trial that uses established research networks with IRB reliance 
agreements in place, but also to test comparative efficiencies of different IRB reliance agreements and to serve 
as a model for assembling similar infrastructure to run multicenter clinical trials for any rare disease. 
Translation: Comparatively testing existing IRB reliance models and will inform translation by determining 
which is the most efficient on key factors that often delay or slow clinical trials.  Statistical considerations: 
We will investigate the relative efficiency of each network by comparing their sites using outcomes: number of 
days to IRB approval and number of days from regulatory approval until the first patient is enrolled. Our first 
key metric will be IRB Duration (as defined in the proposed CTSA Common Metrics): “the time in days 
between the date that the application for IRB review is received by the IRB office and the date of final approval 
granted by the IRB with no IRB-related contingencies remaining.” Our second metric is time from IRB approval 
to first enrollment—will track efficient study start-up processes once IRB approval has been granted. Since 
these are time-to-event outcomes we will use Bayesian Weibull models, including a censoring indicator for 
sites that may not have achieved an event within the study time, to assess this metric. We will follow rates of 
accrual across the different networks, and determine demographic features which could affect accrual rates.  
We will compare regulatory efficiency to KUMC’s (GPC), and UC BRAID past values on these metrics. 
Identifying mechanisms to improve these metrics address an intermediate barrier to getting trial results into 
practice for ultimate patient health benefit. 
This model of assembling research networks using existing infrastructure in a study-specific fashion can 
directly benefit patients with rare diseases, by allowing the assembly of the large multi-institute trials which will 
be necessary to bring scientific rigor to testing new therapeutics, but also pragmatic questions of patient care. 
Partnership: Dr. Richard Barohn is the overall study PI and KUMC CTSA PI and is responsible for 
coordinating all members of the study team.  He will work with his collaborating CTSA PIs Drs. Lars Berglund 
(UC Davis) and Ralph Sacco (Miami) to ensure smooth operation of the informatics and regulatory conduct of 
the study.  The lead ALS doctors, Michael Benatar (Miami), Bjorn Oskarsson (UC Davis), and Jeffrey Statland 
(KUMC) will coordinate within their respective CTSA CC to ensure smooth recruitment and retention of ALS 
patients across all 25 sites.  Dr. Barohn, an experienced ALS multicenter trial investigator, is the PI on two 
FDA-OPD R01 ALS studies (for rasagiline and memantine). He has led the Western ALS (WALS) Consortium, 
participates in the Northeast ALS (NEALS) Consortium, and been on the executive committee of the ALS 
Research Group (ALSRG). He was instrumental in developing the ALS Common Data Element Forms 
(ALSCDE). Dr. Sacco, CTSA PI at the University of Miami, is Chairman of Neurology and was the PI of the 
Northern Manhattan Study which described the greater incidence of stroke in the Hispanic population. Dr. 
Berglund has been the PI of the UC Davis CTSA since 2006 and is the Senior Associate Dean for Research at 
the UC Davis School of Medicine.  He has extensive experience with both basic and clinical research, serving 
as PI for several NIH R01 grants.  Michael Benatar, MD, PhD is a Professor of Neurology at the University of 
Miami, Chief of the Neuromuscular Division, Executive Director of the Kessenich Family ALS Center, and holds 
the Walter Bradley Chair in ALS Research.  He is the PI for CReATe (U54), an FDA funded trial of arimoclomol 
in SOD+ familial ALS (R01), the ongoing MDA and ALSA funded Pre-symptomatic familial ALS (Pre-fALS) 
study, and the University of Miami NeuroNEXT hub (U10).  Björn Oskarsson, MD is an Associate Professor at 
the University of California – Davis and directs their Multidisciplinary ALS clinic. He has been in numerous 
clinical treatment trials and epidemiological studies in ALS. Jeffrey Statland, MD is an Assistant Professor of 
Neurology at KUMC, helps run both MDA and ALSA clinics, is a current CReATe ALS research fellow, and co-
investigator on the GPC ALS projects. 
Barriers: 1) IRB Reliance, and IRB coordination between CTSA CC sites – by building on existing consortia 
that use IRB reliance agreements and selecting sites with a history of working together, we expect to 
accelerate the timeline for study approval. The three CTSA CCs are committed to working together to solve 
issues in a timely fashion that may come up in start-up (see Letters of Support).  
Defining Success: We have already developed 3 research networks involving 20 CTSA sites.  We are going 
to demonstrate cooperation among the 3 networks, with regard to recruitment and trial innovation.  We will 
determine if any network has superior efficiency and why.  We will then disseminate our experience to the 
entire CTSA community via the CTSA leadership channels.  
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Aim 1b. We will create a patient engagement plan which incorporates the patient voice into all aspects of the 
clinical trial.  
Collaboration: Increasingly, collaboration with patients has become critical for translational research.  True 
patient engagement reflects commitment to transparency, the practice of open, bidirectional communication, 
and an appreciation for the lived experience that only patients can provide as members of the research team. 
Investigators at the 3 lead CTSA sites have decades of community-engaged and community-based 
participatory research experience in frontier, rural, minority, disease-specific, and underserved communities in 
diverse geographic settings (FL, CA, KS) and are skilled at meshing investigators’ concerns with those of 
participating patients, communities and stakeholders.  Our investigators have a history of maintaining ongoing 
personal relationships with ALS patients and other stakeholders relevant to this application. These trusted 
relationships have and will continue to provide the project with established connections to further engage 
patients in and with this study. The community/patient engagement faculty from the 20 CTSA sites will serve as 
models to assist the non-CTSA participating sites that may not have established engagement programs.  
Our comprehensive framework for patient engagement is the “ALS engagement ecosystem” (Figure 2), 
developed and refined with patient input. Each engagement element informs the other, and each makes a 
unique contribution. The model is a visual tool that ensures investigators understand the complex and unique 
contributions the non-academic members make to the team. It also is a useful reference point for addressing 
organizational and representational issues for decisions at all levels and for the design of the study.  
 
The approach for this project stemmed from 
ongoing dialogue with patients and families – 
many of whom knew they would not likely benefit 
from participation given their advancing ALS.  
Using facilitated discussion groups, these 
individuals asked the investigators to 
operationalize the “cocktail” design they 
discussed.  Our ALS physicians discussed this 
issue with their patients and conversations 
yielded overwhelming support for a drug 
‘cocktail’ approach to therapy. Using this 
information, we then convened a patient and 
patient/caregiver dyad focus group by phone (to 
reduce transportation and cost burden to participants). 
Four key findings from this focus group helped shape the approach for this study: 
1. First, patients shared enthusiastic support for a multidrug study and agreed that better 
understanding the specific treatments proposed in ALS PATIENTs DEMAND would benefit patients. 
2. Second, the patients and caregivers were passionate about ensuring that the study would be 
available to as many patients as possible.  They discussed this topic at length. They understood that 
opening inclusion criteria would require more patients, and they suggested using functional criteria 
for inclusion, rather than disease duration. 
3. Third, the participants said they preferred to use their personal computers or tablets to input their 
own patient-reported outcomes. Patients, as well as caregivers, were unanimous in sharing how 
stressful and energy-draining additional study visits are for both of them, so they want to provide as 
much information from home as possible. 
4. Finally, the group overwhelming wants to stay involved throughout the study and to continue to 
advise and help in any way possible—especially in dissemination strategies that will assist the ALS 
community to learn about the study’s findings.  
They called on the investigators to be bold, to “think big,” and to do all they could to remove barriers in 
order for more patients to become involved in research that could lead to better treatments. We look 
forward to continuing to work with our patient and caregiver partners. 
 
Innovation: In addition to patient and caregiver input already obtained for the study design we will keep 
patients and caregivers involved throughout the running of the clinical trial. 
 We will designate patient engagement leaders at each of the CTSA CCs 
Figure 2. ALS Engagement Ecosystem 
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 We will create patient engagement circles and identify a pool of patients and their caregivers who 
can be called upon on an as-needed basis for focus groups to address specific study concerns 
regarding conduct, recruitment, and retention 
 We will designate patient/caregiver representatives to formally participate in the ALS PATIENTs 
DEMAND study Steering Committee 
 We will use both patient-representatives and our patient engagement circles to help disseminate 
study findings, as well as leverage existing patient outreach technologies from the MDA and ALSA 
clinics, and CReATe Connect ALS patient registry  
Each of the 3 CTSA CCs will have engagement facilitator to ensure efficient and effective engagement 
activities at the network level. A lesson learned from our early work is that designated patient engagement 
leaders who can reach out and communicate with the entire engagement ecosystem need to be in place at 
the earliest possible point of the project. This ensures a consistent liaison function between the various 
engagement stakeholders and ensures maintaining fidelity so that no aspect of the study moves forward 
without the input or review from relevant stakeholders. For most participating sites, these trained site 
engagement facilitators will be the staff of their CTSA award community engagement programs. In addition 
to engaging patients as collaborators and full members of research teams, our patient engagement 
activities will address effective mechanisms for encouraging patients to become participants in research.  
Translation: Comprehensive engagement, necessary for translation, must include active stakeholder 
involvement in project oversight, monitoring and leadership functions, not just for recruitment. We include 
stakeholders on all project committees and at all stages of the research, from early concept development 
through dissemination of findings. We will hold monthly team meetings (using GoToMeeting, or phone 
conferencing) to discuss study status. Patient representatives, site investigators, and data and safety 
monitoring board members will be on these calls.  The specific composition of these groups will be 
established to ensure perspectives and input from patients, caregivers, MDA and ALSA clinics, and the 
CTSA CC engagement officers.  We are sensitive to not burdening patient/caregiver/family stakeholders 
and overtaxing individuals willing to participate in this work. For example, participation at in-person team 
meetings can be exhausting, so use of online meeting resources like GoToMeeting.com and telephone 
conference calls that can be done from home always will be offered. Likewise, meeting times will be 
variable to be as convenient as possible for everyone.  
We also will adopt a novel online platform developed at the Mid America Chapter of the ALSA.  This 
innovation introduces a strategy to encourage camaraderie and increase knowledge penetration about the 
study.  Co-developed with a private health IT firm, (HeartToHeart Network, LLC), the ALS Care Portal 
provides a way to communicate effectively and on an ongoing basis with ALS patients and facilitating the 
translation of our findings.  
Upon completion of this study, we will establish a study communication committee composed of volunteers 
from our patient and caregiver collaborators and from registry and advocacy partners (MDA, ALSA, 
Prize4Life, and the CReATe Connect Registry). Results will be communicated through the broad network 
of ALS specialty centers from all 3 networks (GPC, UC BRAID, and CReATe). The ability to mobilize patient 
and caregivers and engage them at each stage of the ALS PATIENTs DEMAND study, and to partner them 
with investigators and patient advocates will create an environment where all major stakeholders are 
directly involved, thus maximizing the impact of potential study findings, and accelerating their 
implementation into ALS clinical practice. 
Ultimately the success of ALS PATIENTs DEMAND 
is a collaborative effort (Figure 3).  By combining 
three large existing networks, using ALS specialty 
centers, many which operate ASLA and MDA clinics, 
and bringing the patient voice into trial planning and 
conduct, we will create a flexible, highly leveraged 
ALS trial infrastructure, responsive to individual site 
level concerns and individual patient concerns, and 
will use this network to test combination therapies to 
halt disease progression in ALS. 
 
  
Proposed Stuff 
60 
Figure 3. Effective research into rare diseases is a collaborative effort – from the patient, to patient 
organizations, to ALS physicians. ALS PATIENTs DEMAND is built on CTSA infrastructure.  
 
Barriers: Maintaining patient engagement throughout the complete study process is one major barrier for this 
aim.  We have a track record of maintaining patient engagement through our PCORI sponsored projects.  We 
already have a strong commitment from patients and caregivers to serve on our Steering Committee. As any 
study is a fluid process, and success requires adapting to unforeseen circumstances, we have identified CTSA 
CC engagement leaders who will adapt our engagement efforts throughout study conduct. 
Defining Success: We will develop a broad engagement plan, demonstrate which engagement initiatives 
are the most successful, and disseminate the lessons across the CTSA consortium, and ALS research 
networks. We will define success for this aim as 1) established patient engagement circles and use of topic-
specific focus groups to help with conduct, recruitment, and retention; 2) engaged patient representatives; 
and 3) a dynamic communication committee for study result dissemination.  
 
Aims 1c-e. We will use EHR-defined computable phenotypes for patient screening, and compare this 
approach to traditional recruitment strategies in the clinic or via patient advocacy groups. We will leverage the 
availability of EPIC downloadable ALS clinic templates for the primary set of outcomes to compare outcomes 
collected by this EHR-i2b2 interface with those collected by using REDCap database links within the local clinic 
work-flow. We will implement a patient visit and adverse event monitoring system via a two way web-based 
video system already in production to reduce the burden of participation and ensure retention. 
 
Collaboration: ALS PATIENTs DEMAND includes 25 sites with varying capabilities for EHR-i2b2 (Informatics 
for Integrating Biology and the Bedside)(21) interface and different EHR systems (e.g. Epic/Cerner).  Despite 
the diversity many features unite the study sites—including membership in broad research networks (GPC, UC 
BRAID, and CReATe), and most importantly, the underlying CTSA infrastructure resources (e.g., REDCap) at 
20 of the proposed sites.  We will build on the informatics infrastructure set up by the CTSA CCs to implement 
broad data ‘packages’ that will be within the technical operating capabilities at each site.  Russ Waitman, PhD, 
PI of the GPC and head of informatics for the KUMC site, will take an overall coordinating role for this project. 
KUMC Informatics has integrated and augmented two widely used CTSA technologies (REDCap(22) and 
i2b2(21)) to CReATe HERON (Healthcare Enterprise Repository for Ontological Narration)—an i2b2-based 
data repository of EHR data from the KU Hospital and clinics integrated with biospecimen, a research 
participant registry, and national data—and have used REDCap as a low cost method for data capture and 
secure data delivery from HERON.(23)  KUMC Informatics also has extensive experience through its 
leadership of the GPC, a PCORnet Clinical Data Research Network (CDRN) of 12 sites associated with 8 
CTSAs and geographically dispersed over 1300 miles.(19)  We have invested a major effort to develop and 
publish open source rich Extract/Transform/Load (ETL) software methods to facilitate data and methods 
sharing and are solidly positioned to tackle and contribute to new informatics advances in support of 
translational science. Dr. Waitman will work collaboratively with his counterparts at UC-Davis (Nick Anderson) 
and the University of Miami (Nick Tsinoremas).  The ability to leverage existing PCORnet initiatives like an 
EHR-i2B2 interface and computable EHR phenotypes (GPC and at UC BRAID sites), and the ability to build on 
the common CTSA REDCap infrastructure, will maximize the roll out of existing technologies.  While logistically 
challenging the data innovations proposed here are feasible within the time frame of the grant. 
 
Innovation: For the ALS PATIENTs DEMAND we will implement the following innovations: 1) we will use 
EHR computable phenotypes to assist with patient recruitment; 2) we will collect outcomes during the clinic 
work flow using an EHR-i2b2 interface, or customized REDCap link built into standard work-flow; and 3) we will 
use two way video to follow AEs or perform study visits for patients not able to travel into clinic. 
 
Recruitment: At sites which have the capability (GPC, UC BRAID), we will use EHR computable 
phenotypes defined by diagnosis, standard diagnosis codes (e.g. ICD10), number of visits, and status as living.  
We will compare this recruitment approach to a standard approach of recruiting patients through clinics, use of 
advocacy groups (MDA and ALSA), and use of the CReATe Connect ALS registry.  
 KUMC will define study cohort computable phenotype and study recruitment strategy using i2b2 
queries developed for the PCORnet ALS cohort characterization.  Recruitment will use a.) Manual  
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screening model (where coordinators enter prescreening info in REDcap), b.) Direct email to REDCap 
workflow for sites for prescreening of patients, and, (c.) MyChart to REDCap for the advanced sites. 
 
 UC BRAID has the University of California Research eXchange (UC-ReX) Data Explorer which enables 
UC investigators to identify potential research study participants at the five UC medical centers.  That 
system can be searched in a similar fashion to the HERON system in the GPC. 
As proof of concept for this approach, the GPC used direct patient input to develop a revised version of the 
ALS Functional Rating Scale (ALSFRS-DEMAND) which patients complete from home.  They then used the 
existing IRB reliance model to approve a protocol to conduct a survey of GPC ALS patients, using EHR 
computable phenotypes to identify patients, and combining survey response data with existing EHR 
demographic data as proof of concept for the approach.  In that study we identified > 2000 ALS patients and 
greater than 50% of those who returned the survey stated they would be interested in participating in a clinical 
trial of combination therapy. 
 Outcome collection: We have designed two pathways for data collection.  Both approaches keep 
protected health information (PHI) local, and transmit de-identified data to the KUMC central REDCap 
architecture.  As shown in Figure 4 below, each site in ALS PATIENTs DEMAND will implement one of the two 
proposed data collection approaches. For Approach 1 (REDCap-only), data will be collected in a site level 
REDCap survey.  For Approach 2 (EHR and REDCap), several sites will pilot this proposed advanced 
approach to data collection that leverages site level Epic-EHRs and REDCap.  
 
For Approach 1, KUMC 
Medical Informatics (KUMC 
MI) will design and develop 
REDCap data dictionaries 
to be used to deploy the 
primary data collection 
instruments in REDCap 
installations at each site. 
Deployment at each site 
will be done via webinars 
with KUMC Informatics 
team members providing 
hands on support. KUMC 
MI team also will help the 
REDCap site teams deploy 
KUMC MI-developed 
REDCap plugins to use for 
notifying both site level and 
KUMC study team members of an occurrence of a Serious Adverse Event. A limited dataset version of the 
REDCap study data shared by the site with KUMC will inform the interim analyses for the Bayesian Adaptive 
Design.  KUMC MI will coordinate with the site REDCap administrators to extract/upload the data and to deploy 
new randomization schedules derived from the interim analysis.   
For Approach 2, sites will leverage EHR data collection and patient portal (MyChart) features in addition to the 
REDCap features of Approach 1. In this approach, patients will complete pre-screening via the site’s Epic EHR 
patient portal, MyChart.  Post-enrollment outcome measures, including ALSFRS, will be documented in the 
EHR along with REDCap. Initial work will involve implementing the EPIC forms and integrating them into test 
and development environments at each site. After validation the forms will be deployed in a production 
environment for use in the study. KUMC Medical Informatics also will develop additional ETL methods to 
integrate the measures collected at each site through their EHR and REDCap into a site-level i2b2 in order to 
enable sharing limited dataset versions of study data with the central study team for interim and final analysis. 
Data extraction will leverage the R Data Builder module developed by KUMC MI.  The ETL code and R data 
builder will be tested at KUMC before distribution to all the sites. KUMC will host substantive, individual 
webinars with each site during installation of the shared code. In addition to these technical webinars, KUMC 
MI will provide training for study coordinators involved at sites implementing either approach. 
 
Figure 4. Informatics Architecture for ALS Patient DEMAND 
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Two-way web based video: KUMC also will leverage its experience deploying secure two way video 
communications through its https://telehousecalls.org application.  Telehousecalls was developed for secure 
in-home patient/caregiver/provider communication with funding from the National Science Foundation and has 
been used to support both pediatric behavioral health and pediatric primary care consults for vulnerable 
populations through a grant from the REACH Healthcare Foundation.(24)  For ALS PATIENTs DEMAND, 
Telehousecalls will be available for patients and caregivers as a platform for communication and assessments 
with providers.  It will be modified to best support this trial with patients who may be affected by mobility issues.  
The ALSFRS-R can be collected via video interview and this two-way video can be used for adverse event 
(AE) reporting.  The latter enables personal interaction and assures participants that their symptom is 
understood investigators that more serious AEs are not missed. This two-way video technology is adaptable to 
a variety of platforms (both PC and Mac, Android and iPhone) and enables patients who can no longer 
physically travel to the clinic for study visits to continue to participate in the study.  
 
Translation: The ability to assemble flexible clinical trial networks using existing CTSA, regional network, and 
NIH funded network infrastructure is transformative for patients with rare diseases like ALS.  Our approach to 
such ‘assembled’ study-specific networks needs to be flexible, and ALS PATIENTs DEMAND will be a model 
for future studies.  Key concepts such as: keeping PHI local; using EHR for both recruitment and data 
collection; using modern communication modalities to facilitate including patients who may not physically be 
able to travel to study centers; and creating work-throughs for assembling networks across multiple institutions 
all are addressed by ALS PATIENTs DEMAND, providing proof of concept that such a study can practically be 
assembled and conducted.   
Partnership: The key partnerships for Aim 1c-e will include the informatics officers at KUMC and the other two 
CTSA CCs, data personnel at each of the 25 participating sites, the local investigators, and the patients and 
caregivers participating in the study. The CTSA framework of sites with informatics people already familiar with 
REDCap makes the informatics portion of this study possible. 
Barriers: Creating a universal REDCap data base with links to local EHRs can be challenging, but we have 
already successfully used the proposed model in a current GPC ALS survey.  For sites where we cannot 
provide live links via the EHR, patients will be provided web browser bookmarks for their tablet or computer. 
Patient selection and recruitment via EHR also can be challenging, but we also already have used computable 
phenotypes to identify ALS patients at the GPC and UC BRAID sites.  That most ALS patients are seen in ALS 
specialty clinics allows us to recruit in clinic, from clinic rosters, or from regional ALSA or MDA patient lists as 
well.   
Defining Success: We will compare the frequency of recruitment via the EHR computable phenotype to 
traditional clinic / advocacy based recruitment.  We will survey both patients and providers regarding data 
capture techniques, to determine if the current model reduces the overall study burden. We will disseminate 
the successful translational science approaches developed here to the CTSA consortium, and use this as a 
model for future ALS studies. 
 
Aim 2. To determine which of three drug regimens added to standard of care has the greatest efficacy for 
slowing ALS disease progression.   
 
Collaboration: ALS PATIENTs DEMAND will be a three-arm, 12 month open label, response adaptive 
response randomized study involving 25 sites (and 20 CTSAs) associated with one of three cooperating 
regulatory networks (Figure 1).  We will enroll 300 ALS participants.  The sites included all have ALS specialty 
clinics, and include: 11 MDA certified ALS clinics; 5 ALSA certified clinics; and 9 clinics which run both MDA 
and ALSA certified clinics.  Many of these sites have considerable experience participating in ALS clinical 
trials, and include: 16 sites who are members of the Western ALS Study Group (WALS) and the Northeast ALS 
Consortium (NEALS), 6 sites who are members of NEALS, and 2 sites who are members of WALS.  Together 
WALS and NEALS have conducted over 21 interventional or observational ALS studies.  Together the ALS 
PATIENTs DEMAND national ALS cohort is over 4700 patients.  ALS patients seen in these clinics represent 
the full spectrum of disease, both genders, all races, and diverse socioeconomic status. Study visits will be 
designed to coincide with routine clinic visits, and will use the EHR patient portal, telephone calls, and video 
conferencing to collect information on patient functional status and adverse events between study visits. We 
will allow study personnel to report outcomes using the EPIC standardized forms via the EHR or via REDCap 
links during clinic visits. 
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Innovation: The key innovations for Aim 2 are: 1) opening up of the entry criteria for the study, 2) the use of 
targeted combinations therapies, 3) the use of a Bayesian Adaptive trial design and the PROACT data set for 
informative priors; 4) entry of study data directly into EHR at the time of clinic visits, and by patients in the 
patient portal between visits; and 5) use of EPIC/EHR downloadable ALS clinic templates.  
 
1) Patient characteristics: clinical trials of experimental interventions in ALS use narrow inclusion criteria 
which exclude most ALS patients by limiting studies to patients with symptom onset within 2 years, and FVC 
>75% predicted.  This excludes more than half of patients who will have FVC < 75% predicted at 
diagnosis(25).  In focus groups patients and their family members made it clear they find this approach makes 
them feel left out of studies of new or promising therapies. They suggested a more reasonable approach for 
inclusion would be by baseline functional status. Therefore, our inclusion criteria will be:  a) A clinical diagnosis 
by a study investigator of ALS; and b) ALSFRS-R ≥ 20 (moderately affected); and our exclusion criteria will 
be: a) Any medication contra-indications for the particular drugs being studied; b) inability to provide informed 
consent; and c) current pregnancy or lactation. 
 
2) Interventions: Considering the seriousness of the disease, the lack of robust efficacy of Riluzole (the only 
approved treatment for ALS), and limited options for further treatment, there remains a pressing unmet medical 
need for effective treatments for ALS. Three of the more promising pathological mechanisms with existing FDA 
registered drugs which could be repurposed for ALS are neuroinflammation, glutamate excitotoxicity, and 
nerve hyperexcitability. By creating drug combination therapies which target multiple pathological pathways we 
may be able to slow progression in a more profound and lasting fashion than any one drug alone. 
 
Inflammation: Inflammatory monocytes and macrophages in the CNS have been shown to be involved both 
pathologically and in the rate of progression in ALS.(26-28) The importance of inflammation has been seen in 
both preclinical and animal model data.(27) The inflammation is associated not only with locally acting 
microglia, but also circulating inflammatory cells, which release cytokines believed to play a role in 
neurodegenerative processes, and to be harmful to motor neurons.(29, 30) Inflammation also is found in post 
mortem tissue from ALS patients.(29) The synthetic nonsteroidal drug tamoxifen is widely used in 
chemotherapy for breast cancer. A phase 2 randomized, dose ranging, selection trial of tamoxifen in ALS 
showed significant improvement in survival (P= 0.04) in those randomized to a 20 mg, 30 mg, or 40 mg daily 
tamoxifen treatment cohorts combined together.(31) For each dosage, survival was better at the higher 
dosage.(32, 33) Tamoxifen also may be neuroprotective – as metabolites have antioxidant actions since they 
are strong intramembranous scavengers of peroxyl radicals.  
  
Nerve Hyperexcitability: Recent studies suggest that neuronal hyperexcitability may play a pathogenic role in 
ALS. Whole cell recordings from both embryonic and early postnatal SOD1G93A spinal motor neurons 
demonstrate increased persistent sodium current.(34, 35) Increased repetitive firing of cortical motor neurons 
following injection of current using current clamp conditions in SOD1G93A mice relative to age-matched 
controls has been shown to correlate with cortical hyperexcitability in the mutant mice.(36) Cell culture models 
for ALS have shown direct toxic effects of motor nerve hyperexcitability.(37, 38)  Mexiletine and ranolazine are 
both FDA approved agents which act to reduce motor neuron hyperexcitability.(39-42).  Ranolazine has been 
shown to block persistent sodium currents believed to play a key role in axonal neuro-degeneration and to 
block brain sodium channel excitability, suggesting both central and peripheral actions on axonal excitability.  
Two small human trials of mexiletine in ALS showed promising early results.(41, 43)  Both studies were small, 
and in the only controlled study they did not see any change in the ALS Functional Rating Scale; however a 
slowing of the decline in respiratory function was seen in the lower-dose mexiletine group, and researchers did 
find a dose-dependent reduction in muscle cramps with mexiletine compared to placebo(44). 
 
Glutamate excitotoxicity: Increased activation of N-methyl-D-aspartate (NMDA)-type glutamate receptors 
accounts, at least in part, for excitotoxic neuronal damage—potentially contributing to a wide range of acute 
and chronic neurologic disorders(45). Memantine is a non-competitive NMDA receptor antagonist that may 
reduce the effects of glutamate mediated excitotoxicity(46). Inhibition of excessive NMDA receptor activity by 
memantine, via a mechanism of noncompetitive open-channel blockade, can ameliorate excessive production 
of NO, protein misfolding, and neurodegeneration(47). Memantine has been shown to prolong survival in a 
mutant SOD1 transgenic mouse model of ALS. The data demonstrated that mutant SOD1 transgenic mice  
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survived longer when treated with memantine than placebo controls (p=0.03)(48). A small open label study of 
memantine suggested a possible slowing in the rate of progression (p=0.10), which persisted in 8 patients 
taking memantine for > 2 years compared to historical controls(49). A second small randomized controlled 
study showed memantine to be safe but did not demonstrate slowing of progression(50).  This study, however, 
was powered to detect a large (50%) reduction in rates of progression, so was likely underpowered for a 
meaningful clinical effect. 
 
Each arm of the study will consist of standard of care (SOC) as detailed in the AAN Guidelines (access to 
Riluzole, PEG for nutrition, and BIPAP as indicated) plus one of three drug combinations:(10) 
1) tamoxifen (20 mg: 2 times/day) and ranolazine (500 mg: 2 times/day); 
2) tamoxifen (20 mg: 2 times/day) and mexiletine (200 mg: 3 times/day); and 
3) tamoxifen (20 mg: 2 times/day) and memantine (20 mg: 2 times/day). 
 
The drug interactions for the proposed study arms were reviewed by a consulting pharmacist PhD. 
 
3) Bayesian Adaptive Design: We can vastly improve the efficiency of our study by using an adaptive 
Bayesian study design, informative priors and interval analyses to adapt randomization during the study to 
favor drug combinations which interval analyses suggest are beneficial. Informative priors can be drawn from 
The Pooled Resource Open-Access ALS Clinical Trials data base (PRO-ACT), the largest database ever 
created of clinical data on ALS patients.  PRO-ACT contains over 8500 fully de-identified clinical patient 
records, and more than 8 million longitudinally collected data points. Patients will be randomized to one of 
three treatment arms (groups) with a maximum number of patient’s nmax= 300 (see Protocol Synopsis for 
specific power calculations and modeling). The primary endpoint used to drive adaptive randomization and 
stopping criteria is: the average disease progression (monthly measures of ALSFRS-R) from enrollment to 52 
weeks. A longitudinal model using early estimates from 26 weeks will allow early adaptive randomization to 
promote a smaller, faster, but more powerful trial.  Interim analysis will occur after 100 patients have 52 week 
data and every 8 weeks thereafter.  These data will inform an updated adaptive randomization schedule. We 
will “stop for success” if the probability a treatment is best is > .965. For interim analyses, all data are used on 
all enrolled patients with at least 26 weeks of data. For the final analysis: (1) a treatment is best if pr(it is best) 
> .95 or (2) a treatment is loser if pr(it is best) < .01. It was deemed the most likely effect size will be a disease 
progression of 1 point/month for usual care, but only 0.75 point/month for the best drug combination (an effect 
size greater than current SOC)(8) . For example, in the “One Best” case, the study design has 94% power to 
find the best treatment with an estimated 238 subjects, trial duration of 135 weeks, and 47% of the subjects in 
the winning group. Type I error rate is 5%. A pre-specified subgroup analysis, suggested by our patient group, 
will use a Bayesian ANOVA to estimate the interaction of gender and site of onset with drug. 
 
Translation: By leveraging existing CTSA and PCORnet programs we can accelerate the ALS PATIENTs 
DEMAND milestones (Table 1).  We already have used the EHR to computer phenotype ALS patients, and 
can use this to accelerate recruitment.  The two-way video system is already in production.  We have used 
REDCap surveys embedded in an EHR link, or through web interface, in our PCORnet ALS patient survey.  
 
Table 1. ALS PATIENTs DEMAND 5 year timeline 
The ALS clinical and 
research community have 
agreed on standard 
clinical measurement 
tools to assess outcomes, 
and the ALS PATIENTs 
DEMAND study will use 
these tools.  Standard 
functional and symptom 
scales include: the 
Amyotrophic Lateral 
Sclerosis Functional 
Rating Scale-Revised 
(ALSFRS-R), forced vital capacity, and the ALS Global Impression of Change scale.(51) These scales have  
  
  Study Year 
Aim Milestone 1 2 3 4 5 
A
im
 1
 
IRB      
Patient Engagement      
Screening EHR-defined phenotypes      
Two way video / AE      
EHR-i2b2 data package / REDCap      
PRO Outcomes via Web/Tablet      
A
im
 2
 Recruitment      
Clinical Trial      
Analysis / Dissemination       
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largely been adopted by the ALS PATIENTs DEMAND clinics at this time, and because of the simplicity of 
these forms, the ease of creating REDCap surveys for the forms, and a commitment from Electronic Privacy 
Information Center (EPIC) to make them available to clinics using EPIC EHRs, it is feasible to collect them in 
ALS PATIENTs DEMAND. 
 
Primary outcome: Functional status is the primary outcome.  The ALS Functional Rating Scale (ALSFRS) 
was designed to assess the ability of ALS patients to perform activities of daily living and to detect functional 
changes during clinical trials(52). Precedent for using this scale in clinical trials stems from the only positive 
treatment trial of riluzole in ALS, which showed slower decline in treated patients relative to placebo(53, 54).  
The ALSFRS-R, a revised version of the ALSFRS, is a quickly administered, by research personnel or study 
staff, (five minutes) ordinal rating scale that assesses capability and independence in 12 functional activities. 
These include six bulbar-respiratory functions, three upper extremity functions (writing, cutting food, and 
dressing), and three gross motor functions (walking, climbing, and turning in bed). Each activity is recorded to 
the closest approximation from a list of five choices, scored 0-4, with the total score ranging from 48 (normal 
function) to 0 (no function).  The ALSFRS-R has been used extensively in previous clinical trials and validity 
has been established by correlating ALSFRS-R scores with quantitative strength testing and changes in 
strength over time (55-63). 
 
For this project we further revised the ALSFRS-R and created the ALSFRS-DEMAND. We modified the 
ALSFRS-R so that it would be patient user friendly and so patients could fill it out themselves. The ALSFRS- R 
was sent to approximately 20 ALS patients throughout the GPC region and their caregivers. They were asked 
if the scale was difficult to understand; if there were items they felt should be dropped from the ALSFRS-R; or if 
new items should be included. We held two focus group conference calls where the patients discussed and 
commented on the scale. Patient focus group recommendations included a need for clarification in meanings 
of some of the words in the ALSFRS-R, but overall the impression was that this instrument reflected the types 
of functional limitations they experienced on a daily basis. However, there also were several items patients 
believed should be added to the ALSFRS-R: a question about pain; a question about emotional liability; and a 
general non-denominational question about faith. These were added and our new ALSFRS-DEMAND survey is 
designed to be completed by patients between clinic visits and can be completed via the EHR patient portal or 
an individualized email link to a REDCap database. 
 
Currently Riluzole is the only approved medication for patients with ALS, which extends life by only 2-3 
months. If any of the drug combination proposed here proves effective in ALS, this will have a dramatic and 
immediate impact on patients, their family members, and communities.  All of the proposed drug combinations 
are readily accessible registered FDA medications used for other indications, and should be available in 
generic formulations by the end of the study.  It would be expected most ALS patients interested could obtain 
access to the proposed treatments, and so benefit. In addition if the study design innovations proposed here 
prove feasible this also may transform the way we approach therapies in ALS by: 
Partnership: ALS PATIENTs DEMAND is fundamentally a partnership between the patient and caregivers 
who will have an active role in study design, conduct, and dissemination of results; the engagement officers; 
the patient advocacy groups who will have role in recruitment and dissemination; the GPC, UC BRAID, and 
CReATe who will provide regulatory oversight; and the 25 participating ALS specialty clinics across the 
country. 
 
Barriers: Rolling out a Bayesian adaptive design across multiple CTSAs across the country will be 
challenging.  However, we have used this approach to randomization in a current PCORI sponsored study 
evaluating pain medications in patients with small fiber neuropathies.  The current model of using the EHR-
i2b2 interface or REDCap links embedded in the clinic workflow allows a backup mechanism built into the 
study design to ensure we will be able to perform interim analysis and adjust randomization.  Difficulty with 
recruitment is another challenge.  We believe our combined networks, which cover approximately 4700 ALS 
patients, and the broadening of our inclusion criteria, will lessen this challenge for our goal of recruiting 300 
participants.  However, if we do encounter difficulty we will add additional sites and assign them to their closest 
regional CTSA CC. 
 
Defining Success: The ultimate success of this study would be to identify a treatment arm which slows down 
ALS progression.  In addition we will consider ALS PATIENTs DEMAND successful if we: 1) meet our  
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enrollment and study completion timeline; 2) if at least half of the sites can enter data directly into the EHR at 
the time of clinic visits (the remainder using REDCap links), and this can be successfully abstracted; 3) if 
patients can use the patient portal to enter data between study visits; and 4) use of two way video for adverse 
event monitoring.   
 
Ultimately developing the infrastructure proposed for ALS PATIENTs DEMAND, demonstrating the feasibility 
of conducting a large national multi-site study, and disseminating the innovations in efficiency back across the 
CTSA consortium will provide a viable model for repurposing drugs for use in ALS, and for testing new 
therapeutics for rare diseases, and potentially any disease.  
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RESUME AND SUMMARY OF DISCUSSION: This is a new application for the Collaborative 
Innovation Award, Clinical and Translational Science Award (CTSA) Program (U01) from the University 
of Kansas Medical Center entitled “ALS Patients Demand.”
The purpose of this application is to create a model for building infrastructure to run multisite-studies in 
rare diseases by leveraging existing resources, and the applicants plan to use the CTSA-based 
national research infrastructure to test the hypothesis that drug combination therapy in amyotrophic 
lateral sclerosis (ALS) will be more effective than standard of care alone. Strengths of the application 
include the urgent need for drug combination therapy studies to target ALS as single drug therapies 
failed to stop the disease progression; the well-experienced Principal Investigator (PI); the plans to 
integrate existing coordinating centers from Clinical and Translational Science Institutes (CTSIs) and 
rare disease networks; the plans to use Bayesian adaptive designs in the proposed three arm clinical 
trial of three drug combinations in ALS patients; and the excellent resources at the partnering 
institutions. The plans to use electronic health records (EHRs) in addition to RedCap to identify subjects 
and transmit data and video conferencing for study follow-up visits are additional strengths. The 
proposed patient engagement plan to involve stakeholders from early stages of study design and the 
plans for patient-driven clinical trial to assess ALS combination therapies are innovative. Weaknesses 
include the lack of clear information on how interim metrics will be obtained from three institutional 
review boards and the three CTSA hubs to improve the regulatory submissions or recruitment efforts 
and the inadequate information on the expected side effects of the proposed combination drug 
therapy. Although there are plans to conduct trial visits of patients by video conferencing, there are 
no alternate plans described to visit them if they cannot participate by video. The lack of systematic 
pharmacovigilance during the clinical trial and of a real time, study-wide, centralized live database 
are major weaknesses that will have an impact on the ability to implement adaptive randomization 
and interim analyses, and also increase the risk for human subjects. This resulted in a rating of 
unacceptable for protection of human subjects.
Overall, the application received an Impact/Priority Score of 41; the committee recommended the 
budget as requested. 
DESCRIPTION (provided by applicant): New translational science tools and approaches for more 
rapidly advancing health research to the common goal of improved cures and treatments are especially 
needed for studies of rare diseases. Amyotrophic lateral sclerosis (ALS) is a rare progressive 
neurodegenerative disorder caused by loss of motor neurons in the brain and spinal cord which is 
invariably fatal. Traditional approaches to developing therapies have failed in ALS, yielding only a 
single FDA approved therapy with a modest benefit on survival. Thus, there is a pressing need for new 
therapeutic approaches in ALS. Accumulating evidence points to multiple pathological processes being 
active in ALS – this raises concerns that the disease cannot be halted or slowed by simply targeting 
one of these mechanisms. One approach used to treat cancer and HIV has been to use drug 
combinations targeting different pathological pathways. The goals of this application are 1) to create a 
model for leveraging existing national research initiatives and new translational science tools to build 
the infrastructure to run multi-site studies in rare diseases; and 2) as proof of concept, to use this 
CTSA-based national research infrastructure to test the hypothesis that drug combination therapy will 
slow disease progression in ALS. Several institution level innovations will make such a study feasible. 
We will Ieverage IRB reliance agreements across 3 large networks (comprised of 25 sites and 20 
71
CTSAs) to increase the efficiency of regulatory oversight. We will build on principles of patient 
engagement we utilized in focus groups to involve patients and caregivers in the design, conduct and 
dissemination of results for our study. We will maximize the use of the electronic health records (EHR) 
to identify eligible participants using automated systems based on diagnosis codes and clinic visits. We 
will build a large REDCap data infrastructure based on the common underlying CTSA infrastructure, 
and compare data collection using REDCap to data capture using EPIC downloadable ALS clinic 
templates and the EHR-i2b2 interface. We will implement a two way web-based video system for 
adverse event reporting, and to enable ALS patients no longer physically able to come to clinic to 
remain in the trial. All of the institutional level innovations will complement innovations at the level of the 
clinical trial. We will utilize a Bayesian response adaptive design to test which of 3 drug combinations is 
most effective in slowing disease progression in ALS. If any of the drug combinations proposed here 
prove to be effective in ALS, this will have an immediate impact on patients, the family members, and 
communities. All of the proposed drug combinations are readily accessible medications currently 
prescribed for other indications which could be repurposed for ALS, and all should be available in 
generic preparations by completion of this trial. Our proposed collaboration among CTSA Coordinating 
Centers and model for assembling study-specific infrastructure will not only serve as a blueprint for 
future clinical trials in ALS and other rare diseases, but also will inform all multi-center clinical trials 
seeking to more efficiently maximize network-level collaboration to study any disease.
PUBLIC HEALTH RELEVANCE (provided by applicant): Amyotrophic lateral sclerosis (ALS) is a 
devastating neurodegenerative disease affecting the voluntary motor system which is invariably fatal. 
Patient focus groups expressed overwhelming interest in using a drug `cocktail' approach to ALS 
therapy, with drugs targeting different pathological pathways. We will create a national network of 
CTSA sites and implement novel innovations in patient engagement, regulatory oversight, patient 
recruitment, and outcome collection to conduct a patient-driven clinical trial to assess which of 3 drug 
cocktails are the most effective in slowing disease progression in ALS: the ALS Patient-Driven 
Electronic- based Multidrug Adaptive Network Design clinical trial (ALS PATIENTs DEMAND).
CRITIQUE
Critique 1
Significance: 1
Investigator(s): 1
Innovation: 5
Approach: 4
Environment: 1
Overall Impact
Therapeutic development in rare disorders is severely limited by the number of available subjects and 
their possibility to participate in trials. In fast aggressive diseases like ALS, the time it takes to initiate 
trials directly and negatively impacts the number of available subjects. Despite the availability of 
national networks and CTSAs, there is still a need for better coordination of efforts to increase 
recruitment and accelerate trial initiation. New technology offers the possibility of remote patient 
participation in trials, minimalizing the site visits, very burdensome in this disease. A separate problem 
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that has been plaguing ALS and other rare disorders, is the failed attempts to halt or stop the disease 
progression by targeting one abnormal pathway at the time (one trial-one target), in diseases where 
multiple pathways combine to cause a rapid, irreversible pathology.  This ambitious application sets up 
to both, create a supra structure to efficiently run large, multicenter clinical trials in ALS  (Aim 1) and to 
test this structure while investigating the first combination therapy approach (Aim 2) to ALS. Both aims, 
if successful, can have a great impact in the field of ALS therapeutics, as well as set up the bases to 
similar approaches for other rare disorders. If successful, this project has the potential to highly impact 
the field.  The impact of this application is diminished by the lack of tight pharmacovigilance. Though 
the drugs proposed for combination are FDA approved, with the subsequent large amount of available 
safety information, their systematic long term combination is unique to this study and has not 
undergone rigorous toxicology evaluation. Though adverse events (AEs) reporting is clearly delineated, 
there is a lack of systematic and centralized laboratory and AEs pharmacovigilance, which could 
identify safety signals before they become an issue. Since these combination trials are most likely to be 
conducted by academic networks such as this one, the investigators need to establish industry-
standard safety and data monitoring.
Significance
Strengths
 This application addresses a critical barrier to therapeutic studies in ALS: time to study initiation
and patient recruitment and multi-target therapeutic approach. Despite large advances in ALS
pathophysiology and genetics, ALS clinical trials, one after another, have been disappointing,
failing to translate encouraging pre-clinical (and small clinical) study results. The reasons might
lay on the study design, but also on the fact that in very rapid and aggressive diseases like ALS
a single target approach is likely to provide very small benefit, and thus result in negative trials.
Combination therapy, however, introduces another challenge, requiring much larger number of
subjects to adequately power the studies. This application addresses these issues by providing
a plan to create a supra-structure including three CTSA hubs and 25 centers across North
America, including all the well-established ALS networks, to increase efficiencies in regulatory
approval and patient recruitment.
 The application also includes utilizing clinical EHR in addition to RedCap to identify subjects,
collect and transmit data. They are making a tremendous effort to include patient’s input in all
aspects of the trial, which is the mandate in rare disorders. It is also bringing telemedicine into
the trial design, which will facilitate patient’s participation and follow up. Even if partially
successful, this application will provide valuable information on how to conduct these large
multi-center trials in an academic setting, and what kind of efficiencies (or deficiencies) might
result from such efforts. It has the potential to change how the field is moving forward and as
such it is highly significant.
Weaknesses
 Lack of systematic pharmacovigilance during the clinical trial and of a study-wide centralized
live database increases the risk for human subjects and adds unnecessary risk to the overall
conduct of the study.
Investigator(s) 
Strengths
 Excellent, experienced investigators, all leaders in the field of ALS therapeutic research.
 Investigators have history of collaborating and participating in multi-center ALS trials.
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 Three CTSA hubs are involved in the project, with the central hub being at University of Kansas
Medical Center.
Weaknesses
 None.
Innovation 
Strengths
 Though none of the proposed methodologies or concepts are novel, these are novel in the field
of ALS.
 Video conferencing for study follow up visits and patient portal and involvement in trial design
and data dissemination are clear strengths.
Weaknesses
 Large supra-structures to conduct clinical trials and combination trials have been established for
decades in the field of oncology and HIV, and are thus not novel.
Approach
Strengths
 Aim 1 will provide metrics on different institutional review boards (IRBs) reliance and central IRB
approval methods, which could result in more efficient, unified regulatory submissions in future
trials.
 Three different coordinating centers will be used to accelerate regulatory approvals and
launching trial at the 25 centers by dividing efforts, increasing trial initiation efficiencies.
 Patient engagement and input is sought from the conceptualization of the clinical trial to the data
monitoring and dissemination.
 Clinical databases (Electronic Health Records (EHR)) will be used to identify patients for trials.
The investigator shows feasibility, successfully identifying more than 2000 ALS patients through
EHR phenotyping, fifty percent of which returned a survey positively backing up combination
therapy trials.
 It could be efficient to integrate the clinical EHR and Epic databases and RedCap for data
collection and for patient recruitment, though this also could be a very time-consuming effort
and very error prone.
 Combination therapies are needed for ALS. The drugs chosen for this trial have a clear rationale
and target important pathological pathways, and proof of activity has been shown in animal
models or small trials. The investigators have thought about the pharmacodynamics interactions
that could affect data results and consideration to these are included in the data analysis plan.
 Primary outcome for the trial is ALS progression as measured by one well-established,
validated, clinical relevant functional scale. This makes the study simple, cheaper, and relevant.
Though the lack of biomarkers could result in a type 2 error, the bar is set high for disease
modification and that is reasonable.
 A Bayesian adaptive design will help to delineate wining combinations and potentially decrease
the needed number of subjects.
 The PIs have addressed barriers and proposed alternative plans.
 There are clear plans to disseminate results and to measure success of the projects.
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Weaknesses
 Although Aim 1 is strong on its conceptualization, it becomes weaker on the outcome front. It
is not clear how the metrics to be obtained from the three types of IRBs and the three CTSA
hubs’ recruitment efforts will be translated into improving the mid-way regulatory submissions
or recruitment efforts. Since the study is large and will last at least five years, it would have
been stronger to have interim data analysis of Aim 1 metrics, and use this information to
correct or improve ongoing regulatory submissions and recruitment efforts based on what is
being learned from the first years.
 The main weakness of this application is having three different CTSA hubs acting as
separate coordinating centers, including the collection and management of interim data. A
lack of centralized live database hinders the clinical trial pharmacovigilance. They propose a
risk-based review, randomly performed by each CTSA hub. Though AEs are clearly being
collected and transferred monthly to a central database, laboratory analysis are said to be
reviewed only by PIs, and data not entered and transferred on electronic case report forms.
Monitoring of AEs will be done at each one of three CTSA hubs and then every four months
reviewed by a Data and Safety Monitoring Board (DSMB). That means that there is no
continuous, centralized pharmacovigilance, where one person or team will be looking at trends
in labs and AEs study wide. This could result in safety signals being missed until a significant
AE is reported.
 The DSMB will review data every four months, and it is not clear that this includes labs (not
mentioned). Though these are FDA approved drugs, they all have a significant side effect
profiles and their combination has not been systematically studied in humans or toxicological
studies.
 The lack of a central data system also introduces several potential complications, which will
make the study implementation and conduct inefficient and error prone. There are no
centralized data quality check tools and no data monitoring plan. Since they will be using a
Bayesian adaptive design, they would rely on clean, real time data, arriving to some central
location, and it is not clear how they will smoothly achieve this with once a month limited data
transfers and no ongoing data management and  cleaning.
 They have plans to conduct trial visits by video if patient cannot come to the site, but no
systematic efforts to have a home nurse visit the patient to collect vitals and blood work. The
latter should be part of any missed visit to assure patient is safe.
 Inclusion criteria are broad, which is good, but there is no statistical language on how the
heterogeneous population will be taken into account in the data analysis.
Environment
Strengths
 The central coordinating centers, and all participating institutions, are ALS centers of excellence
and well established research networks.
 There are letters of support from all three IRBs.
 The project builds on the existing strengths and resources of the CTSA program, and at the
individual investigators Institutions and CTSA hubs.
Weaknesses
 None.
Protections for Human Subjects
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Unacceptable. Though the drugs proposed for combination are FDA approved, with the subsequent 
large amount of available safety information, their systematic long term combination is unique to this 
study and has not undergone rigorous toxicology evaluation. Though AEs reporting is clearly 
delineated, there is a lack of systematic and centralized laboratory and AEs pharmacovigilance, which 
could identify safety signals before they become an issue. This is an unacceptable risk to humans.
Inclusion of Women, Minorities and Children
Acceptable. Study will recruit both sexes and adults. Children are not included, as ALS is very rare in 
children.
Vertebrate Animals
Not Applicable.
Biohazards
Not Applicable.
Select Agent Research
Not Applicable.
Resource Sharing Plans
Acceptable. The investigators propose clear ways of sharing and disseminating study results.
Budget and Period of Support
The budget for a centralized, systematic pharmacovigilance monitoring and reporting is not included. 
The safety monitoring budget is at 0.12 calendar months per year. This is a very low effort for 
pharmacovigilance in a 300 patient trial. The data management relies on one person with an effort of 
4.8 calendar months per year. It appears low for the type of decentralized database and potential 
issues that could be found from different sources.
Critique 2
Significance: 2
Investigator(s): 1
Innovation: 1
Approach: 4
Environment: 3
Overall Impact
ALS is a devastating progressive disease, where few therapeutic options exist.  Translation from pre-
clinical efficacy studies in mouse models to efficacious approaches in human patients has largely failed, 
leaving patients few options for treatment.  This application plans to establish a trans-CTSA clinical trial 
7 ZTR1 CI-9 (01)1 U01 TR001815-01
BAROHN, R 
Proposed Stuff
76
network for ALS clinical studies, leveraging key domain expertise at participating institutions.  A key 
goal is to begin combination therapy clinical trials; an approach that patients are requesting.  The 
application is highly innovative in many ways.  There is extensive patient engagement in trial content, 
focus and design, and an ongoing elaborate means of soliciting patient feedback.  This is extended to 
encouraging contact between patients through established infrastructures.  The application takes the 
important strides made in different coordinating centers, both within Clinical and Translational Science 
Institutes (CTSIs), and outside (e.g. Clinical Research in ALS and Related Disorders for Therapeutic 
Development (CReATe)), and works very hard at integrating these.  The combination drug trial, 
requested by patients, is also highly innovative, particularly the use of the Bayesian adaptive design, 
the ALS Patient-Driven Electronic-based Multidrug Adaptive Network Design (ALS PATIENTs 
DEMAND) clinical trial patient recruitment and phenotyping tools, and broad inclusion criteria.  The 
weaknesses centered on feasibility.  The applicants have chosen to tackle a large number of problems 
such as integration of networks, multiple coordinating centers, broadening of inclusion criteria with new 
outcome measures, three drug combinations (where there is scant evidence that each shows efficacy 
in ALS individually), and large-scale patient involvement simultaneously.  Any one of these is important, 
with significant innovation if successful.  But with such a large (n=300 patients) and complicated study, 
there is a relatively high risk that the data once (and if) obtained may be difficult to interpret.  There are 
also significant side effect profiles for each drug individually, and concerns about combined side effects 
(over and above drug metabolic interaction). 
Significance
Strengths
 ALS is a relatively common neurological disorder with no effective treatment.  Efforts to develop
therapeutic approaches are highly significant.
 Efforts to leverage and integrate multiple existing networks are highly significant.
Investigator(s)
Strengths
 The proposed investigative team is outstanding.  The PI brings extensive clinical trial and
clinical experience in ALS to the collaborative network.  The participating CREATE network and
CTSA hubs all have extensive resident experience to carry out the proposed roles.
Innovation
Strengths
 The model of integrating different existing coordinating centers both from the CTSIs and rare
disease networks under the umbrella of broader CTSI infrastructure is innovative.  There are
clear strengths to the participating institutions and great strides that have been made in data
collection and access, and trans-center data queries.
 The patient engagement aim is innovative.  There is increasing recognition that stake holders
should be involved from early stages of study design, and the EU seems to be ahead of US in
this.  The proposed (relative elaborate) effort to include stake holders is impressive, and
innovative.
 The patient-driven desire to undertake a clinical trial of combination therapies is innovative.
 The use of Bayesian adaptive designs in the proposed three arm clinical trial of three drug
combinations in approximately 300 ALS patients is innovative.
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 By focusing on repurposed drugs, there is no need for the complication of an IND.  A letter from
FDA confirmed this.
Approach
Strengths
 The proposed ALS DEMAND network describes an interesting structure, where there are three
sub-hubs managing a total of 25 recruitment sites.  The major hub is the Kansas CTSI (parent
institution of the ALS DEMAND network) managing 14 sites, a University of Miami site
managing an existing network of four ALS recruitment sites (CREATE network), and the UC
system UC BRAID network servicing four recruitment sites via UC Davis.  The rationale
provided is that this will share the workload, thus gaining efficiencies.  In fact Aim 1 will test this
rationale by providing metrics during the trial (Aim 2) startup phase, comparing each site in
terms of IRB approvals, contracts, initial enrollment, and subject accrual metrics.
 Aim 1b describes a patient engagement plan. This is very well described and impressive in
scope and depth.  This is a major strength.
 The application builds on existing network strengths, including the CREATE ALS network.
 Patients’ phenotypes will be collected using a computed method via an integrated EHR between
the 25 sites.  The applicants acknowledge that there is significant heterogeneity between sites
regarding i2b2, EHR systems, and computing infrastructure.  Integrating the EHRs to the point
of computable phenotypes sounds intimidating.  However, the applicants provide a good
example of receiving data on 2,000 ALS subjects via the GPC on ALSFRS-DEMAND at home
survey.  It could be argued that this is a small step towards integrated computed phenotyping
via EHRs, but a step in the right direction nonetheless, and a strength.
 The applicants propose two distinct data acquisition methods (RedCap alone;
EHR/RedCap/Epic).  While this is inclusive of heterogeneous sites, it also complicates the
conduct of an already complex trial.
Weaknesses
 Typically clinical trials have a single coordinating center.  The structure of three coordinating
centers is unusual.  While it is stated that this will share workload and gain efficiencies, this
rationale is not entirely transparent.
 The applicants wish to promote combination therapy trials.  These are often problematic, as the
individual drugs may not have shown efficacy individually, optimization of doses is made much
more challenging when studying multiple drugs simultaneously, and developing effective clinical
trial designs to accurately monitor both safety and efficacy can be difficult.  The investigators
cite both HIV and cancer as success stories.  While they are indeed success stories, one could
argue that key biomarkers were critical to the successful testing of combination therapies in
these (viral load in HIV; molecular targets in cancer).  ALS seems to lack such key biomarkers,
and thus the translation of success in HIV and cancer may not be easily accomplished in ALS.
 There are many well-established ALS clinical trial networks.  The CREATE network is integrated
into the proposed CTSI large network via University of Miami.  However, the applicants should
provide a clear contrast to these pre-existing resources, providing a justification for how the
proposed CTSI network is value added.  Indeed, there is considerable overlap in the proposed
U01 project and these pre-existing ALS-focused networks.
 Including stake holders in the consideration of clinical trial designs, while innovative, is also
risky.  As the applicants describe, the patients would like combination therapies across a very
broad range of disease severity.  Of course, this same inclusiveness can make a trial very
difficult to carry out, with the risk of disparate outcome measures with variable relevance to
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specific disease subgroups.  As the combination drug design (sans biomarkers) is already quite 
challenged, adding the broad inclusion criteria may lead to a trial stands a risk of not providing 
much interpretable data, and thus could become unethical in its broad inclusion.  Similarly, the 
effort to promote patient communication during the trial with the ALS Portal is innovative, it 
stands the risk of introducing additional bias as well, further complicating interpretation of 
outcome data.
 The bulk of the proposed study is to carry out a three arm clinical trial of three drug
combinations in ALS. The rationale for choosing these drugs, as well as the doses, is not well
described.  It is acknowledged that this is a short grant application, and there is not adequate
room for a thorough justification.  The choice of tamoxifien as an anti-inflammatory agent is
not well justified.  Moreover, each of the drugs individually has side effect profiles, and this is
not discussed adequately.  Tamoxifen is reported to cause reduced cognition.  Mexiletine has
been reported to show nausea in 40%, coordination problems in 10%, and tremor in 13% of
patients.  Memantine was halted in trials of multiple sclerosis due to problems with
neurological impairment.  Ranolazine shows dizziness in 10% and constipation in 10% of
patients.  All these side effects could be viewed as exacerbating the ALS disease process.
Environment
Strengths
 There are multiple proposed participants, and thus multiple environments.  Overall, the
combined environment is outstanding.
Weaknesses
 There are acknowledged challenges with integrating the multiple networks.
Protections for Human Subjects
Acceptable.
Inclusion of Women, Minorities and Children
Acceptable.
Vertebrate Animals
Not Applicable.
Biohazards
Acceptable.
Resource Sharing Plans
Acceptable.
Critique 3
Significance: 2
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Investigator(s): 2
Innovation: 3
Approach: 4
Environment: 2
Overall Impact
The investigators propose to utilize CTSA-based national infrastructure to conduct a clinical trial to 
evaluate drug combination therapy to slow disease progression in ALS.  They will take advantage to 
IRB agreements between sites to improve efficiency in regulatory oversight and hence expedite study 
start-up and mid-stream approval of protocol revisions.  They will utilize existing data capture resources 
at the sites to recruit and collect data from patients.  They also propose to use Bayesian adaptive 
design to treatment randomization and early stopping. The investigators will also include input from the 
community members (patients and caregivers) in their design, conduct and dissemination of study 
results. While the investigators propose a bold initiative to conduct a large trial in a rare disease with no 
real treatment option, there are limitations in their approach that will impact adaptation of their 
methodology to other rare diseases.  Key limitations include informatics support and lack of an existing 
network with IRB agreements to expedite study start-up.
Significance
Strengths
 The investigators aim to test drug combinations to slow the progression of ALS using vast CTSA
infrastructure.  If successful, it will be a major breakthrough in providing treatment options to
ALS patients.
 The investigators hope to provide an example of how to utilize CTSA infrastructure to conduct a
multi-site trial.
Weaknesses
 The methods proposed to implement the trials may not be readily transferable to other trials or
disease areas.
Investigator(s) 
Strengths
 The applicants have put together a strong team of experienced researchers that are likely to
succeed in their efforts.  The role of each CTSA hub is well defined.
Innovation 
Strengths
 The investigators propose to utilize several existing approaches to successfully conduct an
important trial in ALS patients.  These concepts that have been tested and evaluated in other
settings include: use of central IRB or use of existing IRB agreements in a network of sites;
incorporating patient and community input in design, conduct and dissemination of study results;
use of EHR to screen potential patients; use of two-way web based video to reach and capture
key data from patients with mobility issues; and use of adaptive design for randomization and
early stopping for efficacy or futility.
Weaknesses
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 Some of these concepts may not be easily transferable to other rare disease populations.
Approach
Strengths
 The overall study design is reasonable with a good likelihood of achieving the objective of
testing the hypothesis that the proposed drug combinations will slow the progression of ALS.
Weaknesses
 The key weakness, a function of independent databases at each CTSA hub, is the data
collection and management system.  The lack of a central data system makes the study
implementation very in-efficient, resource intensive and potentially error prone.  There is no real
time central database with monthly downloads of data from individual sites.  There are no
centralized data quality check tools.  Safety reports cannot be real time either.  Every update of
CRFs will be time consuming and cannot be pushed from a central system.  These will have an
impact on the ability to implement adaptive randomization and interim analyses.  This is not an
ideal model to emulate for other studies.
 It is not clear why the KUMC IRB is developing informed consent forms and disseminating
updates to study protocols.  This is a task typically held by lead study PI and their staff.
 The use of time from IRB approval to first enrollment to evaluate IRB performance does not
make sense.  The application suggests that they expect some sites will not enroll any participant
hence the need to censor time to first enrollment.
 While the idea of expanding inclusion criteria makes sense, it would be good to account for
patient’s baseline status in primary analysis or use some sort of stratified randomization
approach.  The impact of patient’s functional status at baseline on primary endpoint is not
addressed.
 While the proposed Bayesian adaptive design seems reasonable, the investigators should have
presented why this method is preferable over other adaptive designs.
 The study timeline should allow for at least six months of data analyses after last patient last
visit.  The current plan can have patients in follow-up in Year 5 of the grant.
 The timing of interim analyses (100 in some places and 90 in other) and statistical descriptions
are confusing. It is not clear whether the primary outcome change from baseline or functional
rating scale at 12 month follow-up.
 It is not clear if all interim data from a patient will be used to predict 12 month score or just the
six month value.
 Risk based monitoring is not at all described.
 It is not clear if the drug will be labeled for the study and also if patients are expected to pay for
the drug costs.
Environment
Strengths
 The environment is adequately suited for successful completion of the trial.
Protections for Human Subjects
Acceptable.
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Inclusion of Women, Minorities and Children
Acceptable. Children are not expected to be in this study as the median age of disease diagnosis is 
around 60 years.
Vertebrate Animals
Not Applicable.
Biohazards
Not Applicable.
Select Agent Research
Not Applicable.
Resource Sharing Plans
Acceptable.
Budget and Period of Support
Adequate.
THE FOLLOWING SECTIONS WERE PREPARED BY THE SCIENTIFIC REVIEW OFFICER TO 
SUMMARIZE THE OUTCOME OF DISCUSSIONS OF THE REVIEW COMMITTEE, OR REVIEWERS’ 
WRITTEN CRITIQUES, ON THE FOLLOWING ISSUES: 
PROTECTION OF HUMAN SUBJECTS (Resume): UNACCEPTABLE 
Though the drugs proposed for combination are FDA approved, with the subsequent large amount of 
available safety information, their systematic long term combination is unique to this study and has not 
undergone rigorous toxicology evaluation. Though AEs reporting is clearly delineated, there is a lack of 
systematic and centralized laboratory and AEs pharmacovigilance, which could identify safety signals 
before they become an issue. This is an unacceptable risk to humans.
INCLUSION OF WOMEN PLAN (Resume): ACCEPTABLE 
INCLUSION OF MINORITIES PLAN (Resume): ACCEPTABLE 
INCLUSION OF CHILDREN PLAN (Resume): ACCEPTABLE 
COMMITTEE BUDGET RECOMMENDATIONS: The budget was recommended as requested.
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Footnotes for 1 U01 TR001815-01; PI Name: Barohn, Richard J.
NIH has modified its policy regarding the receipt of resubmissions (amended applications). 
See Guide Notice NOT-OD-14-074 at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-
14-074.html.  The impact/priority score is calculated after discussion of an application by
averaging the overall scores (1-9) given by all voting reviewers on the committee and
multiplying by 10. The criterion scores are submitted prior to the meeting by the individual
reviewers assigned to an application, and are not discussed specifically at the review meeting
or calculated into the overall impact score. Some applications also receive a percentile
ranking. For details on the review process, see
http://grants.nih.gov/grants/peer_review_process.htm#scoring.
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